{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicj5nggfojt3zuk33ikpdoszfvfz3upsxan7cmycc43eyj2rujyhu",
    "uri": "at://did:plc:4mqx2cnkm23xwapwlkvqd7bq/app.bsky.feed.post/3mj2sgqgezx42"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicl4w4xljiwji4kem2kgi432iamyg6bztik65xunhke3zah7meys4"
    },
    "mimeType": "image/jpeg",
    "size": 59857
  },
  "path": "/business/story/2026-04-09/this-rich-pharma-company-has-miracle-drug-for-hiv-why-is-it-refusing-to-license-it-worldwide",
  "publishedAt": "2026-04-09T10:00:00.000Z",
  "site": "https://www.latimes.com",
  "textContent": "Gilead's lenacapavir could transform the fight against HIV — but only if millions more patients can get it.",
  "title": "This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people"
}